Page 133 - 《中国药房》2025年6期

rial hypertension in ALK receptor tyrosine kinase-positive [35] LOW A T，HOWARD L，HARRISON C，et al. Pulmonary
lung cancer patient：adverse event or disease spread?[J]. J arterial hypertension exacerbated by ruxolitinib[J]. Hae‐
Thoracic Oncol，2019，14（2）：e38-e40. matologica，2015，100（6）：e244-5.
[26] AWADA C，GROBS Y，WU W H，et al. R-crizotinib pre‐ [36] MIYAWAKI H，KIOKA H，SATO K，et al. Long-term ef‐
disposes to and exacerbates pulmonary arterial hyperten‐ fects of the Janus kinase 1/2 inhibitor ruxolitinib on pul‐
sion in animal models[J]. Eur Respir J，2021，57（5）： monary hypertension and the cardiac function in a patient
2003271. with myelofibrosis[J]. Intern Med，2020，59（2）：229-233.
[27] MCGREGOR P C， BOOSALIS V， ARAGAM J. [37] KARPOV A A，MIHAILOVA A M，SHILENKO L A，et
Carfilzomib-induced pulmonary hypertension with associa- al. Inhibition of JAK1，2 prevents fibrotic remodeling of
ted right ventricular dysfunction：a case report[J]. SAGE pulmonary vascular bed and improves outcomes in the rat
Open Med Case Rep，2021，9：2050313X21994031. model of chronic thromboembolic pulmonary hypertension
[28] LIOTTA M，ROSE P G，ESCOBAR P F. Pulmonary hy‐ [J]. Int J Mol Sci，2022，23（24）：15646.
pertension in two patients treated with bevacizumab for re‐ [38] CHEN I C，LIU Y C，WU Y H，et al. Proteasome inhibi‐
current ovarian cancer[J]. Gynecol Oncol，2009，115（2）： tors decrease the viability of pulmonary arterial smooth
308-309. muscle cells by restoring mitofusin-2 expression under hy‐
[29] WINTER M P，SHARMA S，ALTMANN J，et al. Interrup‐ poxic conditions[J]. Biomedicines，2022，10（4）：873.
tion of vascular endothelial growth factor receptor 2 sig‐ [39] AKOSMAN C，ORDU C，EROGLU E，et al. Develop‐
naling induces a proliferative pulmonary vasculopathy and ment of acute pulmonary hypertension after bortezomib
pulmonary hypertension[J]. Basic Res Cardiol，2020， treatment in a patient with multiple myeloma：a case re‐
115（6）：58. port and the review of the literature[J]. Am J Ther，2015，
[30] SZMIT S，KURZYNA M，GLÓWCZYNSKA R，et al. 22（3）：e88-92.
Manageability of acute severe heart failure complicated [40] JANG B，JEONG J，HEO K N，et al. Real-world inci‐
with left ventricular thrombosis during therapy for breast dence and risk factors of bortezomib-related cardiovascu‐
cancer[J]. Int Heart J，2010，51（2）：141-145. lar adverse events in patients with multiple myeloma[J].
[31] KWON Y，GOMBERG-MAITLAND M，PRITZKER M， Blood Res，2024，59（1）：3.
et al. Telangiectasia and pulmonary arterial hypertension [41] CORNET L，KHOURI C，ROUSTIT M，et al. Pulmonary
following treatment with trastuzumab emtansine：a case re‐ arterial hypertension associated with protein kinase inhibi‐
port[J]. Chest，2016，149（4）：e103-5. tors：a pharmacovigilance-pharmacodynamic study[J]. Eur
[32] PALASSIN P，MARIA A T J，LADHARI C，et al. Pulmo‐ Respir J，2019，53（5）：1802472.
nary hypertension reported with immune checkpoint in‐ [42] MICHELAKIS E D. Spatio-temporal diversity of apopto‐
hibitors：a pharmacovigilance study[J]. Cancer Immunol sis within the vascular wall in pulmonary arterial hyperten‐
Immunother，2022，71（12）：3093-3097. sion：heterogeneous BMP signaling may have therapeutic
[33] MYLVAGANAM R，AVERY R，GOLDBERG I，et al. Ad‐ implications[J]. Circ Res，2006，98（2）：172-175.
verse effects of immune checkpoint inhibitor therapies on [43] 李志勤，范媛，魏安华. 肺动脉高压药物治疗新靶点及免
right ventricular function and pulmonary arterial dilatation 疫调节治疗策略[J]. 医药导报，2022，41（2）：201-206.
[J]. Pulm Circ，2021，11（1）：2045894021992236. LI Z Q，FAN Y，WEI A H. Current status of new targeted
[34] ZHANG J J，ZHANG S S，XU S，et al. Pulmonary arterial drug treatment and the immunotherapy for pulmonary arte‐
hypertension induced by immune checkpoint inhibitor rial hypertension[J]. Her Med，2022，41（2）：201-206.
combined therapy in a patient with intrahepatic cholangio‐ （收稿日期：2024-09-25 修回日期：2025-02-26）
carcinoma：a case report[J]. Iran J Immunol，2023，20（2）： （编辑：邹丽娟）
240-246.

中国药房 2025年第36卷第6期 China Pharmacy 2025 Vol. 36 No. 6 · 763 ·